Recent Analysts’ Ratings Changes for Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals (NASDAQ: ETON) recently received a number of ratings updates from brokerages and research firms:

• 7/28/2026 – Eton Pharmaceuticals had its price target raised by Craig Hallum from $40.00 to $62.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Eton Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Eton Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $60.00 price target on the stock.
• 7/16/2026 – Eton Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 7/13/2026 – Eton Pharmaceuticals was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/13/2026 – Eton Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Insider Activity

In other news, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $843,064.11. This trade represents a 62.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 150,000 shares of company stock worth $4,853,921 over the last 90 days. Corporate insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.